[Drug therapy of shock].
Shock is to define by clinical symptoms, measurable haemodynamic and metabolic changes, clotting failure and disorders of fluid, electrolyte and acid-base balance. It is essential to remove hypovolemia, acidosis, cardiovascular failure, pulmonary and renal insufficiency. Quite a lot of proved and controversial pharmacological substances are placed at physician's disposal. However, the mortality of cardiogenic shock and gram-negative septic shock is more than 80% respectively 30%, often caused by shock lung or irreversible injury to the kidneys. Shock due to depletion of extracellular fluid, poisoning and acute pancreatitis require specific treatment.
D001639:Bicarbonates / Q000627:therapeutic use; D003681:Dehydration / Q000188:drug therapy; D004088:Dihydroergotoxine / Q000627:therapeutic use; D005665:Furosemide / Q000627:therapeutic use; D005934:Glucagon / Q000627:therapeutic use; D006801:Humans; D008775:Methylprednisolone / Q000627:therapeutic use; D010530:Peritoneal Dialysis; D010952:Plasma Substitutes; D012769:Shock / Q000188:drug therapy*; D012770:Shock, Cardiogenic / Q000188:drug therapy; D012772:Shock, Septic / Q000188:drug therapy; D013148:Spironolactone / Q000627:therapeutic use; D013566:Sympathomimetics / Q000627:therapeutic use; D013806:Theophylline / Q000031:analogs & derivatives / Q000627:therapeutic use
D001639:Bicarbonates; D010952:Plasma Substitutes; D013566:Sympathomimetics; D004088:Dihydroergotoxine; D013148:Spironolactone; D005665:Furosemide; D005934:Glucagon; D013806:Theophylline; D008775:Methylprednisolone
Medikamentöse Schock-Therapie.